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Abstract:  The  use  of  complementary  and  alternative  medicines  including  dietary 
supplements, herbals and special diets to prevent or treat disease continues to be popular. 
The  following  paper  provides  a  description  of  an  alternative  dietary  approach  to  the  
self-management and treatment of cancer, the Bill Henderson Protocol (BHP). This diet 
encourages daily intake of raw foods, a combination of cottage cheese and flaxseed oil and 
a number of supplements. Some foods and food groups are restricted (e.g., gluten, meat, 
dairy). Early background theory that contributed to the protocol’s development is presented 
as  is  a  summary  of  relevant  evidence  concerning  the  anti-cancer  fighting  properties  
of  the  individual  components.  Supplement  intake  is  considered  in  relation  to  daily 
recommended intakes. Challenges and risks to protocol adherence are discussed. As with 
many  complementary  and  alternative  interventions,  clear  evidence  of  this  dietary 
protocol’s safety and efficacy is lacking. Consumers of this protocol may require guidance 
on the ability of this protocol to meet their individual nutritional needs.  
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1. Introduction  
The Bill Henderson Protocol (BHP) is a diet that is proposed to treat cancer and was first described 
in 2004 [1] (p. xiv). The primary daily components are raw fruits, vegetables, gluten free whole grains, 
legumes and a cottage cheese/flaxseed oil mixture [1] (pp. 102–103). Similar to other popularized and 
prescriptive diets, the BHP recommends restriction of some foods (i.e., gluten and all dairy products 
other than cottage cheese) and inclusion of supplements. The supplement list is extensive; products 
containing beta glucan, barley grass, a multivitamin and mineral, and a nutrient combination of green 
tea, L-lysine, L-proline and vitamin C [1] (pp. 126–127). The BHP presents a dietary regimen with 
little evidence supporting its composition. The scientific background supporting the BHP is from 1950 
and  uses  then  known  biochemistry  that  led  to  the  cottage  cheese/flaxseed  oil  combination.  Little 
evidence beyond testimonials exists at this time but public interest persists. The following assessment 
provides the first in-depth analysis of the BHP. 
Classified  under  the  rubric  of  complementary  and  alternative  medicine  (CAM),  the  BHP  is 
promoted as an alternative intervention to conventional cancer treatments. Cancer patients may decline 
or discontinue conventional treatments due to a limited understanding of effectiveness or concern with 
treatment side effects. However they too may be unaware of the uncertainties involved if they choose 
an alternative therapy. CAM information has been regarded as ―empowering‖ as it broadens treatment 
and self-care options [2]. As well, some studies report that CAM is more common among those cancer 
patients who suffer from fears, uncertainties and dissatisfaction with the medical system [3]. The BHP 
holds widespread interest for those who have rejected or experienced failure with conventional cancer 
treatments [4,5]. 
There  is  potential  for  harm  in  embracing  nonconventional  nutritional  therapies  for  disease 
treatment. The BHP is one of many diets utilizing a nutritional approach to decrease cancer risk or to 
treat cancer. Other examples include the Gerson Diet, Hoxsey Herbal Therapy, the macrobiotic diet, 
Manner Metabolic Therapy and Kelley Metabolic Therapy [6]. Little evidence supports the use and 
effectiveness of these diets to treat or prevent cancer. Typical of such diets, one food is incorporated as 
a primary constituent and other foods are eliminated because they are viewed as ―harmful‖. This can 
result in nutrient deficiencies especially if whole food groups are eliminated. Often insufficient energy 
intake results and little attention is paid to recommended nutrient intake from substantiated sources 
such as the Dietary Reference Intakes, Institute of Medicine [7]. 
The BHP is easily accessible to the public via website and the published books ―Cure your Cancer‖ 
(ebook edition 2000, paperback edition 2003) and ―Cancer-Free: Your Guide to Gentle Non-toxic 
Healing‖ (first edition 2004, second edition 2007) [1] (p. ii). A third edition of Cancer-Free was 
released both as an ebook and paperback in November 2008 [8]. Through these books and online 
sources, readers are given justifications for the dietary recommendations of the BHP. These will be 
outlined, and discussed by any available data from current research.  
In May of 2009, the authors collaborated in the development of a survey disseminated to members 
of Bill Henderson’s database. Respondents provided their opinions and experiences regarding Bill 
Henderson’s  products  (e.g.,  books,  newsletters,  website,  forums,  etc.)  and  his  protocol  as  well  
as  describing  their  experiences  with  conventional  medicine,  complementary  and  alternative  Nutrients 2011, 3  
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medicine generally. Some of their comments have been included here. Further details of this study will 
be published elsewhere (manuscript currently under review) [9].  
2. The Basis for the BHP 
The  dietary  suggestions,  restrictions  and  supplements  of  the  BHP  address  the  processes  Bill 
Henderson believes lead to the development of a variety of cancers. They include (1) lack of oxygen to 
the cells, (2) a weak immune system, (3) excessive acidity, and (4) toxicity in the body as a result 
of accumulation  of  tobacco,  alcohol,  asbestos,  and  teeth  that  have  undergone  root  canal  teeth [1]  
(pp. 44–45, 127–128).  
Borrowing from the Budwig Diet: An Historical Basis for Lack of Oxygen 
The BHP incorporates principal components of the Budwig Diet which was developed in the early 
1950s  by  German chemist Dr. Johanna  Budwig (1908–2003). She was a licensed pharmacist and 
published  researcher  [10–12]  with  doctorates  in  chemistry  and  physics  [13]  (p.  4).  Budwig  was 
searching for a diet to treat a variety of degenerative and autoimmune diseases. In the early 1950’s, 
while a senior research scientist in the German Federal Health Office, she observed that many of the 
cancer treating drugs being evaluated contained sulphydryl groups [13] (p. 10). Budwig believed that 
sulphydryl  compounds  were  important  to  cellular  metabolism,  and  in  particular  cellular 
respiration [13] (pp. 97–98). She focused her research on the development of cancer as a consequence 
of an aberration of cellular respiration, that in the absence of sulphydryl groups and/or a fatty acid 
partner,  a  low  oxygen  environment  would  be  produced  that  would  encourage  cancerous  cells  to 
proliferate [13] (pp. 97–98). Note that it was in 1953 the Nobel Prize was awarded to Hans Krebs for 
his discovery of the Citric Acid Cycle [14].  
Budwig’s theory is based upon the work of Otto Warburg (1883–1970) [13] (pp. 11–13). Warburg 
was an earlier Nobel Prize Laureate (1931) for the discovery of the nature and action of the respiratory 
enzyme [15], the first of the so-called yellow enzymes, or flavoproteins [16]. Warburg’s scientific 
efforts  produced  a  large  body  of  work  and  publications  in  highly  respected  journals  such  as  
Science (1928, 1956) [17–19]. According to Budwig, Warburg theorized that cellular respiration, like 
many chemical reactions, was dependent upon substrate availability, specifically a sulphydryl group 
and an unknown saturated fatty acid, which he failed to identify [13] (pp. 11–13).  
Budwig, although supportive of Warburg’s work, believed he was looking for the wrong fatty acid. 
From 1949 to 1952, Budwig and colleague H.P. Kaufmann developed new paper chromatography 
techniques to identify and quantify fatty acids, the success of which she says initiated widespread 
research into blood lipids [20] (pp. 5–6) [21–32]. Budwig describes how in 1953 she applied these 
techniques to blood samples of healthy and sick individuals, documenting the differences in fatty acid 
profiles [13] (p. 101) [24], making her one of the first scientists to question the health implications of 
fat  consumption [20]  (pp.  6–7).  Modifying  the  type  of  dietary  fat  became  the  foundation  for  the 
development of the Budwig Diet [20] (p. 23). The modification and reduction of dietary fats in the 
prevention and treatment of cardiovascular disease and cancer has featured prominently in the last 
50 years of dietary research [33,34].  
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3. A Rationale for the Dietary Components: Restoring an Oxygen Rich Environment 
Budwig believed that patients with cancer required highly unsaturated fatty acids (HUFAs now 
referred to as PUFA’s or polyunsaturated fatty acids), specifically linoleic acid (LA) and linolenic acid 
(LNA) to act as raw materials for cell membrane formation and to drive cellular respiration [13] 
(pp. 97–98). Diets lacking these fatty acids offered limited substrate for reactions and resulted in an 
oxygen poor environment, impeding cellular metabolism. Flaxseed oil, which contains 18–20% LA, 
58–60% LNA and lesser amounts of saturated and monounsaturated fat [35], is a key component of 
Budwig’s diet. It was Budwig’s theory that when the highly unsaturated fatty acids of flaxseed oil 
interacted with sulphydryl groups from cottage cheese, the stored energy in the fatty acids would be 
released remedying the oxygen poor environment [13] (p. 102). Mechanisms of carcinogenesis have 
evolved  since  Budwig’s  time.  In  the  last  twenty  years,  acceptance  has  grown  for  endogenous 
mechanisms of carcinogenesis including oxygen free radicals (OFR). OFR’s arise from the cellular 
oxygen  reduction  reactions  and  are  highly  reactive.  They  attack  cell  components  such  as  lipids, 
damage DNA damage and induce mutations [36,37]. 
3.1. Increasing the Solubility of Fats  
The sulphydryl groups, cysteine and methionine, in cottage cheese, were described by Budwig as 
substances that facilitated the mobilization of fat by increasing solubility [20] (p. 30).Through her 
experiments using paper chromatography Budwig found that blending sulphydryl containing cottage 
cheese with flaxseed oil would improve the solubility of the flaxseed oil, a reaction that did not occur 
with the saturated fats derived from pork fat. She reasoned that the sulphydryl groups in the amino 
acids,  hydrogen  bonded  with  the  unsaturated  fatty  acids,  forming  a  lipoprotein [13]  (p. 20). 
Lipoproteins  are  the  building  blocks  of  the  phospholipid  bilayer,  or  as  Budwig  called  them  ―the 
external skin of the cell‖ [20] (p. 17). The proper function of cellular membranes is vital as it mediates 
the flow of materials in and out of the cell. Budwig felt the combination of these two substances 
(i.e., cottage cheese and flaxseed oil) was important because the bond created by the opposing charges 
generated the ―electromotor force‖ of a lipoprotein [13] (pp. 99–100), which she claimed provided the 
only path for fast and focused transport of electrons in biological systems [13] (p. 92). It was not until 
1978  that  Peter  Mitchell  received  a  Nobel  Prize  for  his  work  on  energy  production  in 
mitochondria [38]. 
3.2. Restrictions of the Budwig Diet 
Processed fats, such as the hydrogenated fat found in margarines were prohibited in the Budwig 
diet [1] (pp. 104–106). Budwig believed these solid fats were oxygen inert [20] (pp. 9, 21). She also 
opposed  the  use  of  synthetic  supplements,  such  as  single  vitamins  or  multivitamin  compounds, 
claiming that synthetic nutrients did not function well in the body [13] (p. 43). Further, she felt that the 
use of synthetic antioxidants would block the restoring effect she believed flaxseed oil had on cellular 
respiration [13] (p. 50). There is some recent evidence that the potency of antioxidant effects in plant 
cells  may  differ between natural and  synthetic vitamin E, but Budwig  could only have suspected 
this [39]. Promotion of synthetic supplements is the major difference between the BHP and the original Nutrients 2011, 3  
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Budwig  diet.  The  BHP  suggests  many  vitamin  supplements,  some  exceeding  tolerable  upper 
intake levels. 
4. Cancer and the Budwig Diet 
A conventional cancer theory claims that cancer is a disease involving rapid or uncontrolled cellular 
division as a result of changes in genetic information of cells [40] (p. 31). Errors in replication can 
either kill a cell or cause mutations that may lead to cancer [40] (p. 31). Budwig felt that cancer was a 
result of incomplete cellular division. She claimed that cells would begin the process of mitosis, but 
fail to completely divide due to the lack of substrate required to make the lipoprotein rich cellular 
membrane. The product of incomplete division would then be quarantined by the body through the 
formation  of  a  tumour [13]  (pp.  13–14)  [20]  (pp.  17–20).  This  theory  allegedly  accounts  for  the 
polyploidy, or the presence of multiple sets of chromosomes that can be observed in cancer cells. 
Budwig further claimed that the biochemical activity of highly unsaturated fatty acids would accelerate 
the rate of cell division resulting in the self-destruction of formed tumours [20] (pp. 17–20) [13] (p. 97). 
Today, cancer is considered to be a complex multistep disorder, the result of a combination of factors 
including  exposure  to  radiation  and/or  carcinogens  (damage  to  DNA),  infection,  genetics,  aging, 
immune function disorders, and lifestyle factors such as smoking [41] (pp. 998–1000). 
5. Modifications of the Budwig Diet for Inclusion in the BHP 
In Cancer Free, Bill Henderson recommends principal components of the Budwig Diet but adds a 
variety of other substances that would not have received Budwig’s endorsement. True to prescriptive 
diets that emphasize ritual [42], Henderson suggests precise amounts of the cottage cheese/flax seed 
combination (2/3 cup of 1% or 2% organic cottage cheese (no preservatives), 6 tablespoons flaxseed oil) 
to  be  eaten  immediately  to  avoid  oxidation [1]  (p.  103).  Stevia  (a  natural  sweetener),  almonds, 
strawberries or blueberries are suggested additions to improve palatability and provide antioxidants [1] 
(pp. 102–103). Contrary to Budwig’s recommendations, Henderson advocates the strict avoidance of 
alcohol and meat and encourages the use of artificial antioxidants [1] (pp. 57–59, 121) [13] (p. 50, 
pp. 117–118) [20] (p. 34).  
Lipid Metabolism: A Modern Perspective 
Since the 1950’s we have gained a greater understanding as to how all exogenous fats, regardless of 
type, are absorbed and transported. Through mechanical, enzymatic and hormonal factors dietary fats 
are  melted,  emulsified,  lysed  and  absorbed.  In  the  duodenum,  the  products  of  the  partial  lipid 
digestion, namely monoacyglycerols, lysolecithin, cholesterol and fatty acids, combine with bile salts 
to  form  micelles,  that  are  small  enough  to  access  the  intramicrovillus  spaces  of  the  intestinal 
membrane  [43].  Bile  salts  render  micelles  sufficiently  water  soluble  to  penetrate  the  water  layer 
bathing the enterocytes. Upon interaction with the brush border of these cells, the lipid contents of the 
micelle diffuse out of the micelle and into the enterocyte. Once in the enterocyte most of the products 
of fatty acid digestion are resynthesized to form triacylglycerols, phosphatidylcholine and cholesteryl 
esters.  Short  chain  fatty  acids  enter  portal  circulation  directly  and  are  attached  to  albumin  for Nutrients 2011, 3  
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transportation  to  other  tissue  sites  [43].  Resynthesized  lipids  are  joined  with  protein  to  form 
chylomicrons, apolipoprotein A and B [44] (p. 96). Chylomicrons are excreted from the enterocyte into 
the lacteals, which carry them to the thoracic duct and later into the bloodstream to the liver, muscle 
and adipose tissue [41] (p. 17).  
There was limited understanding of fat metabolism in 1950 to inform Budwig’s theory. While high 
density lipoproteins (HDL) and low density lipoproteins (LDL) had been identified, it wasn’t until the 
1970’s that apopeptides were discovered and their role and the role of lipoproteins in general, was 
more clearly understood [45]. The discovery of the LDL receptor in 1974 (Brown and Goldstein) 
provided the missing link in the understanding of fatty acid transport and the potential role various fats 
could play in human health [46]. In the absence of this knowledge, Budwig erroneously concluded that 
sulfur containing amino acids methionine and cysteine were required for the solubility and transport of 
fatty acids. Sulfur atoms play a role in the formation of esters produced during fatty acid digestion and 
taurine  from  cysteine,  is  a  component  of  bile  salts  [44]  (pp.  95–101),  but  these  were  not  the 
mechanisms upon which Budwig’s theory focused.  
Budwig was strongly opposed to the intake of processed fats. Today, we recognize these fats as 
trans-fats, most commonly produced during partial hydrogenation of vegetable oils to increase the 
shelf life of foods. Trans-fats have been associated with a number of adverse health effects [47,48]. 
The American Dietetic Association, the Institute of Medicine, US Dietary Guidelines, and the National 
Cholesterol  Education  Project  recommend  limiting  dietary  trans-fat  intake  from  processed  foods 
wherever possible based on evidence that has demonstrated that a 2% increase in energy intake from 
trans-fat  is  associated  with  a  23%  increase  in  cardiovascular  risk  [49].  Health  Canada  has  had  a  
Trans-Fat Task Force since 2005 that is poised to mandate recommendations made in 2007 that the 
food industry limit the trans-fat content of vegetable oils and soft margarines to two per cent of the 
total fat content and five percent total fat content in other foods [50].  
There is some evidence to support Budwig’s belief regarding different fats and health implications, 
which we know today to be an important consideration in the development of cardiovascular disease, 
specifically atherosclerosis [41] (pp. 878–880). But at the highest level of evidence, that being meta-
analysis of randomized controlled trials, causality is less certain. In Hooper’s et al. (2001), systematic 
review of 27 randomized controlled trials (30,092 person years of observation) including modified or 
reduced fat intake, they reported a reduction of cardiovascular events of 16% (0.84; 0.72 to 0.99) and a 
reduction of cardiovascular mortality of 9% (0.91; 0.77 to 1.07) [34]. However, The Women’s Health 
Initiative Randomized Controlled Dietary Modification Trial involving almost 50,000 women over an 
8 year period found no significant effect of a low-fat diet on risk of invasive breast cancer or total 
cancer incidence [51]. It would appear that other lifestyle factors including regular exercise, smoking 
cessation, weight reduction, low-fat diet, and reduced alcohol intake have the potential to decreased the 
risk of some cancers, but long term prospective studies are needed to establish causality. In 2005, 
Dietary  Reference  Intakes  were  published  addressing  dietary  fat  and  other  macronutrients  [7].  
The panel of authors state that there is insufficient evidence to set a defined level of fat intake at which 
risk of inadequacy or prevention of chronic disease occurs, but they recommend an estimate of total fat 
would be 20–35% of energy, and have termed that an Acceptable Macronutrient Distribution Range 
(AMDR) [7]. Nutrients 2011, 3  
 
 
7 
The use of flaxseed oil for the treatment of cancer has recently received scientific support but has 
not been studied as extensively as lignans in flax seed. Two studies published in 2010 have shown 
flaxseed  oil  to  increase  the  effectiveness  of  two  drugs  used  for  the  treatment  of  breast  cancer, 
tamoxifen and trastuzumab, by increasing apoptosis and reducing cancer cell proliferation [52,53]. 
However, the use of flaxseed oil in conjunction with pharmaceutical drugs was never intended by 
Budwig or by BHP so these results cannot validate their claims.  
6. The Supplemental Components of the Bill Henderson Protocol  
6.1. Beta-Glucan: Strengthening the Immune System 
Beta-glucan  is  a  complex  polysaccharide  found  in  the  cell  walls  of  bacteria  and  fungi  [54]. 
Henderson  suggests  a  baker’s  yeast  (Saccharomyces  cerevisiae)  derivative  in  a  specified  dose  of 
500 mg/50 pounds body weight taken in the morning in a fasted state [1] (pp. 126–127). This step, he 
purports  will  boost  immune  function,  helping  immune  cells  to  recognize  and  destroy  cancer 
cells [1] (p. 91).  
There  is  a  growing  body  of  research  on  the  use  of  beta-glucan  for  immune  stimulation  and 
modulation, although the research conducted to date has primarily consisted of in vitro studies using 
human cancer cells lines and animal studies [55–59]. Application of the results to human cases is 
limited.  A  2007  study  reported  a  significant  increase  (from  48–50%  to  61–69%)  in  monocyte 
production in 23 women with advanced breast cancer after 15 days of oral ingestion [60]. This has not 
been replicated to date. A recent review article by Chan, Chan and Sze (2009) reported that beta-glucans 
of differing sizes and branching patterns may have variable immune potency and result in a variety of 
clinical  effects.  To  date  there  are  no  high  quality  clinical  trial  data  available  on  assessing  the 
effectiveness of purified beta-glucans and cancer treatment [57].  
6.2. Barley Grass: Countering Acidity 
Barley  grasses  are  the  new  sprouts  of  barley  and  contain  a  wide  range  of  nutrients  and  plant 
hormones.  Henderson  encourages  the  use  of  barley  grass,  considered  alkaline,  to  counter  the  
excess acidity he believes to be a contributing factor in the development of cancer [1] (p. 119). In his 
book Cancer-Free (2007) Henderson makes a claim that barley grass contains 3000 enzymes that are 
used by the body [1] (p. 118). Enzymes are proteins and will be metabolized in the same way as other 
dietary proteins and denatured during digestion. The therapeutic use of supplemental enzymes to treat 
exocrine pancreatic insufficiency is supported, but the supplements manufactured for this purpose are 
pH sensitive and survive strong stomach acid to deliver concentrated, therapeutic doses [61], unlike 
barley grass derivatives.  
Specific evidence supporting the use of an alkaline diet or alkaline supplements in cancer is not 
available. Research on this issue as related to bone health and osteoporosis is somewhat contradictory. 
Arnett (2008) reported that diet or drugs that shift the body’s acid-base balance towards alkalinity may 
be useful for the treatment of bone loss disorders [62]. Research from Canada, also from 2008, showed 
a linear association between changes in calcium excretion in response to changes in acid excretion, but 
it could not be established that the calcium was coming from mobilized bone [63]. In a follow-up Nutrients 2011, 3  
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2010 cohort  study,  it  was  concluded  that  low  urine  pH  from  acid  excretion  is  not  a  predictor  of 
osteoporosis  risk  [64].  How  these  results  might  translate  to  issues  related  to  cancer  has  not 
been elucidated. 
More specific to the BHP, a German study (2009) demonstrated that the use of a multimineral 
supplement containing alkaline ash minerals significantly increased the pH of subjects’ blood and 
urine [65]. If bodily pH does in fact play a role in cancer, this study does suggest that alkalizing 
supplementation could be useful, but this is preliminary research only.  
Although many studies on barley are available, there are no studies related specifically to barley 
grass. The nutritional composition of wheat grass is close to barley grass and in one pilot study of 
60 participants, wheat grass reduced the haematological toxicity related to chemotherapy in breast 
cancer patients [66].  
6.3. Nutrient Mixture: The Claim of Preventing Metastases 
The BHP advocates the use of a nutrient mixture of vitamin C, the essential amino acid l-lysine and 
the non-essential amino acid L-proline. The therapeutic use of this combination was initially described 
by Dr. Mathias Rath and Dr. Linus Pauling in the 1990s [67,68] and is purported to counter the 
mechanisms that lead to the metastasis of cancer [69]. Green tea was added to the nutrient mixture as it 
was found to improve the effect [69,70]. In his book Cancer-Free (2007), Henderson makes the claim 
that this nutrient mixture will slow down or completely stop the spread of the cancer [1] (p. 114).  
The Dr. Rath Research Institute in California conducts research on patho-mechanisms including 
cancer,  and  on  the  beneficial  effects  of  micronutrients  in  various  chronic  diseases.  They  have 
published over two dozen studies from 2004 to 2009 related to the use of the nutrient mixture for 
cancer [71–96]. These studies were performed on human cancer cell lines and mice models. Cancers 
studied include skin cancer, liposarcoma, glioma, osteosarcoma, testicular cancer, melanoma, lung, 
renal  adenocarcinoma,  cervical,  mesothelioma,  bladder,  fibrosarcoma,  ovarian,  mammary,  breast, 
pancreatic,  prostate,  colon,  Ewing’s  sarcoma  and  lymphoma  [71–96].  The  primary  focus  of  these 
studies has been to assess the ability of this nutrient mixture to inhibit the expression of enzymes 
known as matrix metalloproteinases (MMPs). MMPs have been found to be up-regulated
 in nearly 
every  type  of  human  cancer  and  are  correlated  with
  advanced  stage,  invasive  and  metastatic 
cancers [97]. The studies conducted by the Rath Institute showed a dose dependent inhibition of MMP 
expression [71–95].  
Conversely, the only independent study testing this nutrient mixture’s effect on cancer is a recent 
German study involving of an animal model of neuroblastoma. Results suggested that this nutrient 
mixture  was  ineffective  when  tested  on  mice  with  induced  tumours  and  spontaneous  liver 
metastases [98]. A greater amount of objective, independent review of this nutrient mixture would help 
provide a basis for more firm conclusions to be drawn.  
Studies  involving  independent  components  of  the  mixture  do  exist.  Demeule,  Brossard,  Page, 
Gingras and Beliveau (2000) published a study confirming the use of green tea polyphenols to inhibit 
MMP activity in rat and human tissue, with catechins epigallocatechin gallate and epicatechin gallate 
showing the greatest level of MMP inhibition [70].  Nutrients 2011, 3  
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Henderson  credits  Dr.  Rath’s  work  and  suggests  including  the  nutrient  mixture,  but  does  not 
recommend Rath’s brand of expensive supplements [1] (pp. 113–114) (Table 1). Rath’s supplement 
lacks external investigation, raising the possibility of bias for his findings.  
Table 1. Specific brands and doses for supplements suggested in the BHP [1] (pp. 126–127). 
Component  Source recommended by BHP  Daily dose recommended while on the BHP 
Cottage cheese  organic, low fat  2/3 Cup (mixed with flaxseed oil) 
Flaxseed oil  Barleans  6 Tablespoons (mixed with cottage cheese) 
Beta glucan  Transfer Point  500 mg/23 kg body weight 
Barley grass  Green Supreme  20 tablets divided into three doses 
Heart plus  Our Health Coop 
2 capsules/TID, to be taken with green 
tea extract 
Green tea extract  Our Health Coop  1 capsule/TID, to be taken with Heart plus 
Daily advantage  Mountain Home Nutritionals  1 packet/BID (8 capsules/packet) 
6.4. Multivitamin/Mineral Supplement 
The inclusion of this supplement in the BHP is part of the megavitamin trend popularized in the 
seventies.  The  multivitamin/mineral  supplement is  a  combination including  65 vitamins,  minerals, 
essential fatty acids, amino acids, anti-oxidants, digestive enzymes, herbs and ―superfoods‖ (Tables 2 
and 3). A comparison of this combination to the recommended Daily Recommended Intakes (DRI) for 
males and females ages of 51–70 years is provided [7]. Based on data collected from the 2009 survey 
of BHP consumers, the 51–70 years age range were the most frequent users of the BHP [9].  
Table  2.  Supplemental  nutrient  intake  recommended  in  the  Bill  Henderson  Protocol 
compared to Institute of Medicine’s DRIs. 
Nutrient 
Total daily amount 
advised in the BHP 
[1] (pp. 57–59) 
Daily 
recommended 
intake (male  
51–70 y) [7] 
Daily 
recommended 
intake (female  
51–70 y) [7] 
Tolerable 
upper intake 
level (adults 
19–70 y) [99] 
Vitamin A  3030 µ g/10000 IU *  900 µg  or 2970 IU  700 µg  or 2310 IU  3000 µg /day 
Vitamin C  4000 mg *  90 mg  75 mg  2000 mg/day 
Vitamin D  40 µg /1600 IU  10 µg  or 400 IU  10 µg  or 400 IU  50 µg /day 
Vitamin K  120 µg  **  120 µg   90 µg   ND 
Vitamin E  800 IU/536 mg  15 mg  15 mg  1000 mg/day 
Thiamin  100 mg **  1.2 mg  1.1 mg  ND 
Riboflavin  100 mg **  1.3 mg  1.1 mg  ND 
Niacin  352 mg *  16 mg  14 mg  35 mg/day 
Vitamin B6  220 mg *  1.7 mg  1.5 mg  100 mg/day 
Folic Acid  800 µg   400 µg   400 µg   1000 µg /day 
Vitamin B12  200 µg  **  2.4 µg   2.4 µg   ND 
Biotin  600 µg  **  30 µg   30 µg   ND 
Pantothenic acid  300 mg **  5 mg  5 mg  ND 
Calcium  2000 mg  1200 mg  1200 mg  2.5 g/day Nutrients 2011, 3  
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Table 2. Cont. 
Iodine  200 µg   150 µg   150 µg   1100 µg /day 
Magnesium  1000 mg *  420 mg  320 mg  350 mg/day 
Zinc  40 mg  11 mg  8 mg  40 mg 
Selenium  400 µg   55 µg   55 µg   400 µg /day 
Copper  4000 µg   900 µg   900 µg   10000 µg /day 
Manganese  20 mg *  2.3 mg  1.8 mg  11 mg/day 
Chromium  400 µg  **  30 µg   20 µg   ND 
Molybdenum  200 µg   45 µg   45 µg   2000 µg /day 
Potassium  200 mg  4.7g  4.7g  ND 
Choline  200 mg  550 mg  425 mg  3.5 g/day 
Vanadium  0.300 mg  ND  ND  1.8 mg/day 
Boron  2 mg  ND  ND  20 mg 
Quercitin  100 mg  ND  ND  ND 
N-acetyl cysteine  100 mg  ND  ND  ND 
Trace mineral complex  50 mg  ND  ND  ND 
PABA  60 mg  ND  ND  ND 
Inositol  200 mg  ND  ND  ND 
Silica  52 mg  ND  ND  ND 
Rutin  20 mg  ND  ND  ND 
Hesperidin  20 mg  ND  ND  ND 
Beta Carotene  15000 IU  ND  ND  ND 
Tocotrienols  40 mg  ND  ND  ND 
Coenzyme Q10  20 mg  ND  ND  ND 
Alpha lipoic acid  20 mg  ND  ND  ND 
Lutein  12 mg  ND  ND  ND 
Lycopene  6 mg  ND  ND  ND 
EPA (eicosapentaenoic acid)  200 mg  ND  ND  ND 
DHA (docosahexaenoic acid)  300 mg  ND  ND  ND 
Omega 3 fatty acids  100 mg  1600 mg  1100 mg  ND 
Gamma linolenic acid  100 mg  ND  ND  ND 
Ox bile  100 mg  ND  ND  ND 
Pancreatin  100 mg  ND  ND  ND 
Lipase  20 mg  ND  ND  ND 
Cellulase  20 mg  ND  ND  ND 
Maltase  20 mg  ND  ND  ND 
Protease  20 mg  ND  ND  ND 
Amylase  20 mg  ND  ND  ND 
ND: No data are available on a recommended or maximum intake; 
* Intake recommended exceeds the tolerable upper limit (UL); 
** Nutrient exceeds DRI, no UL has been established and caution is advised. 
Six recommended nutrient supplements (vitamin A, C, B6, niacin, magnesium and manganese) 
exceed the tolerable upper intake level (UL), the highest level of daily intake that is likely to pose no Nutrients 2011, 3  
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risk of adverse health effects in most people [99]. Intake levels of vitamin A and C of this magnitude 
are known to cause nausea, vomiting, headaches, and insomnia and diarrhea and abdominal bloating 
respectively  [41]  (pp.  83,  113).  Vitamin  K,  B12  thiamin,  riboflavin,  pantothenic  acid,  biotin  and 
chromium do not have a UL established, but caution is advised when exceeding recommended daily 
amounts (RDA). The BHP suggested intake of these nutrients exceeds the RDA in some cases by 
100 times  or  greater.  Combinations  of  these  nutrients  in  excess  may  result  in  adverse  effects  but 
remain unknown. 
The ―Herbal Superfood Booster‖ (Table 3) contains a list of herbal components and the daily dose 
suggested in the BHP [1] (pp. 57–59). Evaluations from the Natural Standard online database and the 
American Pharmaceutical Association on the efficacy of each are provided, with the increasing health 
risk represented by a letter (A–D) or number (1–5), respectively.  
Table 3. Daily advantage superfood herbal booster. 
Daily advantage 
herbal 
Daily dose 
suggested in the 
BHP 
Natural standard 
grade 
American Pharmaceutical 
Association’s numerical 
value 
Spirulina  1500 mg  C 
(various) 
4 
Turmeric  400 mg  C *  3 
L-Taurine  400 mg  B 
(nutritional deficiency) 
N/A 
Siberian ginseng 
root and extract 
460 mg  C *  2 
Bee pollen  200 mg  C **  3 
L-Carnitine  200 mg  A 
(nutritional deficiency) 
3 
Royal jelly  100 mg  N/A  4 
Astragalus  100 mg  C ***  3 
Ginger root  100 mg  C **  1 
Gymnema sylvestre  100 mg  B 
(diabetes) 
2 
Green tea extract  100 mg  C *  3 
Panax ginseng  80 mg  C  2 
Gingko biloba  20 mg  C ***  1 
N/A: Herbal has not been evaluated by source; * For cancer treatment/prevention; ** For the side 
effects of cancer therapy; *** For cancer treatment/prevention and the side effects of cancer therapy. 
Natural Standard was founded by clinicians and researchers to provide high quality, evidence-based 
information about complementary and alternative therapies [100]. An international collaboration of 
more  than  100  academic  institutions,  Natural  Standard  uses  a  comprehensive  methodology  and 
reproducible  grading  scales,  to  provide  information  that  is  evidence-based,  consensus-based,  and 
peer-reviewed, tapping into the collective expertise of a multidisciplinary Editorial Board [101].  Nutrients 2011, 3  
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The letter grades assigned by Natural Standard are based on the quality and quantity of evidence for 
the use of foods, nutrients and herbs for the treatment of various medical conditions. The letter grades 
are defined as [102]:  
A- strong scientific evidence;  
B- good scientific evidence; 
C- unclear or conflicting scientific evidence;  
D- fair scientific evidence;  
F- strong negative evidence.  
The American Pharmaceutical Association (APA) is a national, professional society of pharmacists 
whose mission is to support pharmacists in their ability to educate and advise the public on the safety 
and efficacy of medicines [103] (p. xi). In their publication Practical Guide to Natural Medicine, the 
APA assessed dietary supplements of herbs and amino acids. Numerical values were assigned to herbs 
and  nutrients  based on the quality and  quantity of available research. The following  is how each 
numerical value was defined: 
1.  Years of use and extensive, high-quality studies indicate that this substance is very effective and 
safe when used in commonly reported dosages. 
2.  According to a number of well-designed studies and common use, this substance appears to be 
relatively effective and safe when used in commonly reported dosages. 
3.  Studies on the effectiveness and safety of this substance are conflicting or there are not enough 
studies to draw a conclusion. 
4.  Research indicates that this substance will not fulfill the claims made for it, but that it is also 
unlikely to cause any harm. 
5.  Studies indicate that there is a definite hazard in using this substance, even in recommended 
amounts [103] (pp. 12–13).  
7. Dietary Restrictions of the Bill Henderson Protocol: Reducing Toxicity 
The  BHP  prohibits  meat,  dairy  products  (with  the  exception  of  cottage  cheese),  gluten,  sugar, 
processed food and alcohol. Links between cancer and diet have been investigated [33,104–106], but it 
is difficult to make general conclusions and by extension, recommendations regarding the restriction of 
entire food groups. The BHP does not take into account calculation of energy needs, which is an 
important consideration for prescribed diets [107]. 
7.1. Meat  
Conclusions about cancer risk and the consumption of meat are difficult to make given the state of 
current evidence. In a case control study from Uruguay (2009), 846 cases and 846 controls were 
followed estimating meat consumption and lung cancer risk. Total meat consumption of red meat and 
processed meat are reported to be associated with an increased risk of cancer, while total intake of 
white  meat,  poultry  and  fish  did  not  increase  risk  [108].  Intake  of  red  meat  also  appears  to  be 
associated with an increased risk of breast cancer [109,110] although the variables controlled in studies 
vary widely such as menopausal status and cooking practices, making it difficult to draw definitive Nutrients 2011, 3  
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conclusions [110,111]. The intake of saturated fat, found in higher amounts in animal products, has 
been linked to breast cancer [33]. Colon cancer risk has also been correlated with intakes of red meat, 
pan fried meat and processed meat mutagens [112]. Fish and specifically the consumption of omega 3 
fatty acids, has been associated with a lowered cancer risk [33,113], and more specifically, decreased 
mortality from prostate cancer [114].  
7.2. Dairy 
A link between cancer and dairy products has not been established, although there are hypotheses 
about  the  risks  of  milk  and  milk  product  consumption  associated  with  an  increase  in  growth 
hormone/insulin like growth factor-1 that is triggered by the ingestion of milk protein [115]. The 
recent publication from the European Prospective Investigation into Cancer and Nutrition reported an 
association between high dairy intake, high serum concentrations of IGF-1 and an increased risk for 
prostate cancer [33]. Conflicting evidence exists regarding the role of dairy in the development of 
colorectal cancer. It has been reported that high dairy intakes during childhood resulted in a near 
tripling in the odds of developing colorectal cancer in adulthood [116]. Conversely, two recent studies 
suggest that a higher intake of dairy products is associated with a lower risk of colon cancer [117,118]. 
High calcium intake has also been correlated with a lower risk of colorectal cancer [117]. Fortified 
milk and milk products are also a source of vitamin D, which has been associated with a reduced risk 
of cancer [119,120]. The BHP recommends a supplement containing 40 µg /1600 IU of vitamin D [1] 
(pp. 57–59), four times the current daily recommended intake of vitamin D. 
7.3. Gluten  
Gluten, found in a variety of grains including wheat, does contain several proteins that are known 
causes of respiratory and food allergies as well as contact hypersensitivity, in certain individuals [121], 
but this reaction is not associated with an increased risk of cancer.  
Celiac disease is described as a small intestine mucosal disorder that is gluten dependent and often 
characterized by nutrient malabsorption, diarrhea and weight loss [122]. A known complication of 
celiac disease is the development of bowel cancers [41] (p. 713). A 2009 article reported that if celiac 
disease was first diagnosed later in life, lymphoma was detected more often than in cases of early 
diagnosis,  the  possible  culprit  being  duration  of  exposure  to  gluten  [123].  The  same  study  also 
postulated that those with celiac disease may actually be at a lower risk of gastric and colon cancers 
than  previously  thought  due  the  celiac  characteristic  symptoms  of  impaired  absorption  and  quick 
excretion  of  fat,  fat  soluble  substances,  hydrocarbons  and  other  potentially  carcinogenic 
substances [123]. In the general population however, an increased risk of cancer from gluten ingestion 
has not been established.  
7.4. Sugar and Processed Food 
Foods high in sugar can replace nutrient dense foods, delivering more calories and fewer nutrients. 
Poor nutrition can lead to numerous health consequences including anemia, delayed immune response 
and  prolonged  wound  healing.  Foods  with  a  high  glycemic  index  have  been  linked  to  insulin 
resistance, which has been correlated with an increased risk for pancreatic cancer [124,125]. In a Nutrients 2011, 3  
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2009 cohort study intended to assess this risk, those with the highest intake of fructose and glucose 
were found to be at higher risk for pancreatic cancer [124]. Positive associations have also been made 
between  diets  with  a  high  glycemic  load  and  both  esophageal  adenocarcinoma  [126]  and  breast 
cancer [127–129].  
High  sugar  intake  is  associated  with  weight  gain  and  obesity.  A  2008  study  reported  that  
―an  estimated  33,966  new  cancers (4%  of  all estimated  cancers)  in males  and  50,535  (7%  of  all 
estimated cancers) in females diagnosed in 2007, or 6% of all cancers, may be potentially attributable 
to  obesity [130].  Without  the  impact  of  rising  obesity  rates,  incidence  rates  might  have  declined 
(instead  of  remaining  stable)  from  1988–1994  to  2001–2004  for  uterus,  breast  and  certain  other 
cancers‖ [130]. The following, by the World Cancer Research Fund and The American Institute for 
Cancer Research, is a list of mechanisms by which obesity can increase cancer risk as reported in their 
publication ―Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective‖: 
  Obesity causes an elevation of insulin and leptin levels, which can promote the growth of cancer. 
Elevated leptin levels are associated with colorectal and prostate cancer. 
  Insulin  resistance  is  increased,  causing  the  pancreas  to  compensate  by  increasing  insulin 
production. Hyperinsulinaemia is correlated with an increased risk of cancers of the colon and 
endometrium, and possibly of the pancreas and kidney. 
  Higher levels of body fat increases the level of estradiol in men and women and may also raise 
testosterone  levels  in  women.  Increased  levels  of  these  sex  steroid  hormones  are  strongly 
associated with endometrial cancer and postmenopausal breast cancer and may increase risks for 
colon and other cancers. 
  Adipose  tissue  promotes  inflammatory  factors  in  the  body.  Obese  individuals  have  higher 
concentrations of interleukin-6, C-reactive protein and tumour necrosis factor. Leptin, which 
again  is  raised  in  cases  of  obesity,  also  functions  as  an  inflammatory  cytokine.  Chronic 
inflammation can increase ones risk of cancer [40] (p. 39).  
There is also a potential link between sugar and cancer involving the effect of sugar on the immune 
system. It has been reported that the daily ingestion of 75–100 g of simple sugars, including glucose, 
sucrose, fructose and honey has been found to induce a fifty percent drop in the activity of white blood 
cells for two to five hours [131]. The immune system plays a central role in the elimination of altered 
and unhealthy cells, including cancer cells.  
7.5. Alcohol 
Alcohol intake has been associated with an increased risk for certain cancers including breast, rectal 
and pancreatic cancers [132–134]. There is conflicting data on the effect of alcohol consumption and 
prostate cancer. While heavy drinking, 50 g or more per day, has been positively associated with 
prostate cancer [135], 36 g or more per day has been shown to decrease the risk of benign prostatic 
hyperplasia [136], a marker for prostate cancer risk. A 2009 study evaluated lifetime alcohol exposure 
and its link to cancer risk in men and concluded that moderate and high alcohol consumption increased 
risk  for  cancers  of  the  esophagus,  stomach,  colon,  liver,  pancreas,  lung  and  prostate.  Cancer 
association was strongest for beer and to a lesser extent spirits [137]. Red wine, on the other hand, may Nutrients 2011, 3  
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offer some protective benefits against a number of degenerative diseases. In a study looking at the 
effect  of  alcohol  on  breast  density,  a  strong  intermediate  marker  for  breast  cancer  risk,  red  wine 
showed a consistent inverse association, unlike other types of alcohol [138]. The protective mechanism 
associated with red wine is often attributed to red wine’s content of resveratrol [139]. A recent study 
suggested that the benefits of red wine include, but are not limited to resveratrol, but may also involve 
its red pigments [140]. Clearly, the type and amount of alcohol consumed is a factor in cancer risk and 
supports Henderson’s recommendation for restriction. 
8. Discussion 
This paper has summarized the available evidence on the anti-cancer properties of the components 
of the Bill Henderson Protocol. Prospective longitudinal studies with intermittent measures are not 
available for testing the efficacy of the BHP. Some data exists on some of the individual components 
suggested as part of the protocol. The protocol was created by Bill Henderson, motivated by his own 
interest in curing cancer [1] (p. xiii). To date, much of the evidence for the BHP has taken the form of 
user testimonials [141,142]. The vulnerability of seriously ill people may increase their susceptibility 
to  attaching  truth  to  testimonials.  Henderson  attempts  to  dissuade  potential  BHP  followers  from 
investing in conventional therapies by challenging the trust consumers typically have in the expertise 
of conventional practitioners and suggesting that they alone can manage their illness [1] (pp. 1–4). 
People may believe that the BHP is as effective as conventional treatment and may choose to forgo 
such interventions, possibly significantly affecting their outcomes.  
As  a  large  component  of  his  six  component  diet,  Bill  Henderson  suggests  cottage  cheese  and 
flaxseed oil recommended by Dr. Johanna Budwig in the 1950s. While it is known that the essential 
fatty acids found in flaxseed oil, as well as methionine and cysteine, are important in human health, 
with modern advancements to our understanding in areas of human physiology, lipid metabolism and 
lipoproteins, Budwig’s fervent belief in these combined substances as cure for cancer appears overly 
simplistic. Although Budwig lived until 2003, and was actively lecturing until the late 1990s, there 
does not appear to have been any attempts to test her theories using modern technology or different 
source materials, such as fish oil.  
An additional constraint to the interpretation and understanding of Budwig’s work is that it was 
originally published in German. While English translations are available, they are primarily copies of 
lectures, letters and transcribed interviews. The foundations of her theory seem at times to be ―lost in 
translation‖ making it difficult to review and evaluate her theories. 
The information available on the supplements that are a part of the BHP is limited. The use of a 
beta-glucan supplement as an immune stimulant does appear to be supported by scientific research, 
although  there  is  still  much  to  assess  about  the  value  of  differing  beta-glucan  sources  and 
concentrations [55,57,58,60]. Similarly, scientific data on the use of barley grass for cancer is limited. 
Barley grass, like wheat grass, is commonly viewed as a highly nutritive food, but the benefits may be 
greatest when the grass is pressed into a juice and consumed fresh. The processing of the grass into a 
powder for use in capsules offers the benefits of convenience and perhaps for some, easier palatability, 
but might reduce some of its nutritive value.  Nutrients 2011, 3  
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The combination of lysine, proline, ascorbic acid and green tea extract has been studied by The 
Dr. Rath Research Institute and based on their published work, has shown this nutrient mixture to be a 
promising  anti-cancer  proliferation  agent  [71–95].  This  has  been  at  least  partially  supported  by 
research into the individual use of green tea extracts or ascorbic acid in cancer treatment [70,143–147]. 
However, the one independent published study on the use of the nutrient mixture as a whole showed it 
to  be  ineffective  against  the  cancer  studied  (neuroblastoma)  [98].  A  greater  amount  of  objective, 
independent research would help provide a broader look at the issue and benefit those looking to draw 
more firm conclusions.  
Adherence to the BHP comes with several challenges; the first being the high number of pills to 
swallow on a daily basis. If one strictly adheres to all the components of the protocol, a minimum of 
46 pills and 6 tablespoons of flaxseed oil are required each day. For cancer patients with digestive 
difficulties, including nausea and/or obstructions, this may not be possible. A common side effect of 
consuming large amounts of oil is nausea and this may impede adherence in taking the full amount of 
flaxseed  oil.  Those  people  intolerant  of  dairy  products  may  find  the  ingestion  of  cottage  cheese 
challenging. If one is able to consume all the required components of the protocol, the doses of certain 
nutrients including vitamin A, C, B6, niacin, magnesium and manganese exceed the tolerable upper 
levels of intake. Depending on the individual, this may or may not produce side effects.  
The possibility of conventional drugs interacting with the protocol supplements may also be of 
concern. For example, those on anticoagulants may be at risk of agonistic effects from an increased 
intake of supplements such as vitamin E, ginger, Ginkgo biloba, ginseng and omega 3 fatty acids, 
which can interfere with the expected therapeutic effects [103] (pp. 269–271, 295) [148].  
The dietary guidelines of the BHP are restrictive, eliminating some of the most common foods in 
the  Western  diet. For many, this drastic dietary change may  be one of the  greatest  challenges  to 
protocol compliance and there is conflicting data about the value of eliminating the restricted foods. 
The  nutritional  status  of  cancer  patients  may  already  be  compromised  by  virtue  of  their  disease 
symptoms and further dietary restrictions may have negative effects such as insufficient energy intake. 
Supplementation  in  excess  of  recommended  dietary  intakes  may  trigger  adverse  effects  that  are 
unexpected. Evaluation of the potential benefits of the BHP in comparison to its potential negative 
effects  in  this  population  needs  to  be  undertaken.  Moreover,  potential  protocol  adherents  are 
encouraged to forgo conventional treatment, albeit for a limited period of time, to try the BHP and 
delay or attenuate treatment with known benefits. 
9. Conclusion 
The Bill Henderson protocol is a dietary approach for the treatment and management of cancer. 
Presently, the protocol as a whole has not been evaluated, although varying amounts of evidence exist 
for some of its components. While there is some historical suggestion of a scientific rationale for this 
protocol, its claims remain unproven. Certainly further study is needed. Future investigations should 
consider whether this protocol meets the nutritional requirements of consumers with cancer and if it 
has any impact on morbidity and mortality in this patient group. Information on dietary information 
needs  to  be  made  available  to  consumer  groups  so  that  they  may  make  informed  choices  when 
undertaking such self-management regimens. Nutrients 2011, 3  
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